AgeX Therapeutics, Inc. (AGE) News

AgeX Therapeutics, Inc. (AGE): $0.57

0.01 (+1.79%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AGE to Watchlist
Sign Up

Industry: Biotech


Ranked

of 495

in industry

Filter AGE News Items

AGE News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

AGE News Highlights

  • AGE's 30 day story count now stands at 2.
  • Over the past 15 days, the trend for AGE's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest AGE News From Around the Web

Below are the latest news stories about AGEX THERAPEUTICS INC that investors may wish to consider to help them evaluate AGE as an investment opportunity.

AgeX Therapeutics Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements

ALAMEDA, Calif., November 25, 2022--AgeX Therapeutics, Inc. ("AgeX": NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on November 22, 2022 it received notification from the staff of the NYSE American (the "Exchange") that the Exchange has accepted a revised listing compliance plan from AgeX and has granted AgeX an extension of time to regain compliance with the Exchange’s continued listing standards as set forth in Sectio

Yahoo | November 25, 2022

AgeX Therapeutics Reports Third Quarter 2022 Financial Results

ALAMEDA, Calif., November 10, 2022--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended September 30, 2022.

Yahoo | November 10, 2022

AgeX Therapeutics Reports Second Quarter 2022 Financial Results

ALAMEDA, Calif., August 12, 2022--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended June 30, 2022.

Yahoo | August 12, 2022

Dr. Joanne Hackett Appointed Chairperson of AgeX Board of Directors

ALAMEDA, Calif., May 18, 2022--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that Dr. Joanne Hackett has been appointed Chairperson of AgeX’s Board of Directors. Dr. Hackett joined the Board of Directors in December 2021. She will serve in a non-executive capacity as AgeX’s Chairperson. Dr. Greg Bailey, who served as AgeX’s Chairperson since 2018, will continue to serve as a member of AgeX’s

Yahoo | May 18, 2022

AgeX Therapeutics Reports First Quarter 2022 Financial Results

ALAMEDA, Calif., May 13, 2022--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended March 31, 2022.

Yahoo | May 13, 2022

AgeX Therapeutics Reports Fourth Quarter and Annual 2021 Financial Results

ALAMEDA, Calif., March 29, 2022--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended December 31, 2021.

Yahoo | March 29, 2022

AgeX Therapeutics to Collaborate With University of California, Irvine, on Research Program for Exosome-Based Therapies for Certain Brain Disorders

ALAMEDA, Calif., December 14, 2021--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today a research collaboration with the University of California, Irvine (UCI) to explore the therapeutic potential of exosomes and other extracellular vesicles produced by neural stem cells derived from AgeX pluripotent stem cells, with the goal of developing therapies to treat adverse neurocognitive effe

Yahoo | December 14, 2021

AgeX Therapeutics’ Licensee ImStem Biotechnology Announces First U.S. Multiple Sclerosis Patient Dosed with IMS001

ALAMEDA, Calif., November 30, 2021--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today that ImStem Biotechnology, Inc. ("ImStem"), a biopharmaceutical company developing human embryonic stem cell (ESC)-derived mesenchymal stem cells, has dosed the first U.S. multiple sclerosis (MS) patient with ImStem’s lead investigational drug candidate IMS001 at the Shepherd Center in Atlanta, GA. I

Yahoo | November 30, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.592 seconds.